The new CellaVision® Bone Marrow Aspirate Application launches in EMEA

CellaVision today announces the launch of its CellaVision® Bone Marrow Aspirate (BMA) Application across the EMEA region, extending its digital cell morphology platform into bone marrow aspirate analysis — one of the most complex areas in laboratory diagnostics.

The application received its CE marking approval as a Class C product under the European Union In Vitro Diagnostic Regulation (EU IVDR) on December 8, 2025, confirming compliance with stringent requirements for safety, performance, and quality.

Bone marrow aspirate examination remains central to diagnosing and monitoring blood cancers and other serious blood diseases. The process is typically manual, time-consuming, and highly dependent on expertise. Peter Wilson, VP Global Marketing at CellaVision highlights that “we are bringing AI-assisted digital workflows to this critical discipline, supporting laboratories in delivering more consistent and traceable results.” By digitalizing key steps in bone marrow morphology, the CE-marked CellaVision BMA Application offers laboratories a solid solution for automating, standardizing, and simplifying the morphological examination of bone marrow aspirates.

CellaVision collaborates with Sysmex Corporation as distribution partner for the CellaVision BMA Application and leverages from already established relationships with hospital and reference laboratories across the region.

The CellaVision BMA Application will be introduced to the laboratory hematology community at the International Symposium on Technological Innovations in Laboratory Hematology, hosted by the International Society for Laboratory Hematology (ISLH) from April 17-19, 2026, in Edinburgh, UK.